下呼吸道治疗市场－全球产业规模、份额、趋势、机会及预测（依疾病类型、药物类别、给药途径、最终用户、地区及竞争格局划分，2021-2031年）

全球呼吸系统药物市场预计将从 2025 年的 360.5 亿美元大幅成长至 2031 年的 589.1 亿美元，复合年增长率为 8.53%。

这个市场领域涵盖用于治疗肺部和气道疾病的药物，例如抗生素、抗发炎药物和支气管扩张剂，这些疾病包括肺炎、慢性阻塞性肺病（COPD）和气喘。推动这一市场扩张的关键因素是需要持续治疗的慢性呼吸系统疾病盛行率不断上升，而全球空气品质恶化和快速都市化对这一趋势产生了显着影响。国际呼吸学会论坛预测，到2024年，每年将有700万人死于与空气污染相关的疾病，凸显了全球对有效肺部治疗方法的迫切需求，也凸显了这个问题的严重性。

儘管市场需求强劲，抗菌药物抗药性仍是一个重大障碍。这种抗药性会逐渐削弱标准抗感染疗法的疗效，导致临床结果恶化。这迫使製药公司必须经历昂贵且复杂的监管流程才能推出新药。因此，这些挑战会加重医疗预算负担，延缓新一代疗法的推出，并阻碍整体市场扩张。

市场驱动因素

全球慢性呼吸系统疾病负担日益加重，是推动全球下呼吸道治疗市场发展的主要因素。气喘和慢性阻塞性肺病（COPD）等疾病的盛行率不断上升，是推动这一市场成长的主要动力。这些疾病需要持续药物治疗来控制症状并预防病情恶化。根据国际药学联盟（FIP）发布的《2024年全球COPD现况报告》，目前全球约有3.91亿人患有COPD，庞大的病患群体依赖维持性治疗。环境因素进一步加剧了这项需求。美国肺臟协会于2024年4月发布的《空气污染状况报告》显示，美国约有1.31亿人居住在颗粒物和臭氧污染水平超标的地区，这直接促使人们对有效的呼吸系统治疗药物产生了迫切需求。

重塑市场的第二个关键因素是生物製药和标靶治疗方法的进步。由于传统支气管扩张剂往往无法有效治疗重症患者，製药开发商正将重心转向精准药物和针对特定发炎路径的单株抗体。这一转变促成了高价值生物製药的成功商业化，并占据了显着的市场份额。例如，再生元製药公司在2024年10月发布的2024年第三季财报中报告称，其旗舰呼吸系统生物製药Dupixent的全球净销售额达到38.2亿美元，年增23%。这一强劲的业绩凸显了标靶治疗的快速普及及其在推动未来市场收入成长方面的重要作用。

市场挑战

抗菌素抗药性持续降低现有抗生素产品的商业性和临床效用，对全球下呼吸道治疗市场的成长构成重大障碍。随着细菌病原体对标准疗法产生抗药性，药物的有效寿命显着缩短，为製药企业带来动盪的经营环境。这种生物进化迫使企业持续投资研发新化合物以取代过时药物，但由于新的抗药性机制出现迅速，投资回报也难以预测。因此，呼吸道抗感染药物研发的高风险阻碍了持续的资本投入，并减缓了整体市场扩张。

克服这种阻力的挑战进一步限制了产品开发平臺的停滞，阻碍了产业成长。检验新药所需的严格监管流程既耗时又昂贵，导致缺乏可立即上市的创新产品。根据国际药品製造商协会联合会（IFPMA）2024年的数据，全球抗生素研发管线中仅有一种候选药物处于III期临床试验阶段，该药物针对的是卫生当局确定的关键优先病原体。后期治疗方案的匮乏限制了产业满足临床需求的能力，限制了收入潜力，并阻碍了该领域的财务进展。

市场趋势

数位健康平台与智慧吸入器的整合正在改变患者护理模式，使其从被动治疗转变为主动药物依从性监测。这些技术利用感测器设备即时追踪药物使用情况，并将数据传输给医疗服务提供者，以便检测用药依从性问题并主动预测病情加重。这个数位生态系统能够实现及时干预，并为患者提供切实可行的呼吸系统健康讯息，从而显着改善临床疗效。根据瑞思迈（ResMed）于2024年1月发布的2024财年第二季财报电话会议，该公司在上年度透过其云端软体和数位健康产品惠及超过1.7亿人。这充分展现了连网呼吸技术目前对患者照护产生的巨大影响。

同时，在监管机构要求减少氢氟碳吸入器对环境影响的压力下，市场正经历着向永续、低碳推进剂装置的关键转型。製造商正积极调整产品系列，以环保替代品（例如HFA-152a）取代全球暖化潜势（GWP）高的推进剂，从而在日益严格的环境法规下确保商业性永续性。这项策略转变既保护了产品生命週期免受高碳气雾剂潜在法律禁令的影响，也满足了对环境友善医疗保健解决方案日益增长的需求。根据《製药技术》杂誌2024年4月报道，凯西製药公司（Chiesi Farmaceutici）正在投资3.5亿欧元开发一种新型吸入器推进剂，预计与2019年相比，该推进剂将使公司范围3的排放减少90%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球下呼吸系统药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依疾病类型（气喘、慢性阻塞性肺病、肺炎、结核病、支气管炎、其他）
  • 依药物类别（抗生素、非类固醇消炎剂、止咳药、鼻减充血剂、其他）
  • 依给药途径（口服、肠外、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美下呼吸道药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲下呼吸道药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区下呼吸道药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲下呼吸道药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲下呼吸道药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球下呼吸道治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lower Respiratory Tract Therapeutics Market is projected to experience substantial growth, increasing from USD 36.05 Billion in 2025 to USD 58.91 Billion by 2031, reflecting a CAGR of 8.53%. This market sector includes pharmaceutical treatments such as antibiotics, anti-inflammatories, and bronchodilators intended to manage conditions affecting the lungs and airways, including pneumonia, chronic obstructive pulmonary disease, and asthma. The primary force driving this expansion is the rising prevalence of chronic respiratory diseases that require ongoing management, a trend significantly influenced by worsening global air quality and rapid urbanization. Highlighting the severity of this issue, the Forum of International Respiratory Societies reported in 2024 that seven million deaths annually were caused by illnesses related to air pollution, emphasizing the urgent global need for effective pulmonary therapies.

Despite this strong demand, the market faces a significant obstacle in the form of antimicrobial resistance, which progressively undermines the effectiveness of standard anti-infective treatments. This biological resistance worsens clinical outcomes and compels pharmaceutical companies to navigate expensive and intricate regulatory processes to introduce new agents. Consequently, these challenges place a strain on healthcare budgets and delay the introduction of next-generation therapeutics, impeding the overall expansion of the market.

Market Driver

The rising global burden of chronic respiratory diseases acts as the primary catalyst propelling the Global Lower Respiratory Tract Therapeutics Market. This momentum is defined by the increasing prevalence of ailments such as asthma and chronic obstructive pulmonary disease (COPD), which require continuous pharmaceutical management to control symptoms and prevent exacerbations. According to the International Pharmaceutical Federation (FIP) in its 2024 'Global State of COPD Report', approximately 391 million people worldwide are currently living with COPD, establishing a vast patient population dependent on therapeutic maintenance. This demand is further intensified by environmental factors; the American Lung Association's April 2024 'State of the Air' report indicates that roughly 131 million people in the United States live in areas with unhealthy levels of particle or ozone pollution, directly fueling the need for effective respiratory treatments.

A second critical factor reshaping the market is the advancement of biologics and targeted therapeutic approaches. As traditional bronchodilators often fail to adequately treat severe cases, pharmaceutical developers are pivoting towards precision medicines and monoclonal antibodies that target specific inflammatory pathways. This shift has resulted in the successful commercialization of high-value biological agents that capture significant market share. For instance, Regeneron Pharmaceuticals reported in its 'Q3 2024 Financial Results' in October 2024 that global net sales for Dupixent, a leading biologic for respiratory conditions, increased by 23% to $3.82 billion year-over-year. This strong financial performance highlights the rapid adoption of targeted therapies and their essential role in driving future market revenue.

Market Challenge

Antimicrobial resistance represents a significant barrier to the growth of the global lower respiratory tract therapeutics market by steadily diminishing the commercial and clinical utility of existing antibiotic portfolios. As bacterial pathogens adapt to survive standard treatments, the effective lifespan of pharmaceutical products is severely curtailed, creating an unstable environment for manufacturers. This biological evolution compels companies to constantly invest in discovering new compounds to replace obsolete drugs; however, the return on investment is precarious due to the speed at which new resistance mechanisms appear. Consequently, the high risks involved in developing respiratory anti-infectives discourage sustained capital investment, slowing the overall expansion of the market.

The challenge of overcoming this resistance further restricts growth by stalling the product development pipeline. The rigorous regulatory processes required to validate new agents are both costly and time-consuming, leading to a shortage of market-ready innovations. According to the International Federation of Pharmaceutical Manufacturers & Associations in 2024, the global antibiotic pipeline included only one candidate in Phase III clinical trials targeting critical priority pathogens identified by health authorities. This lack of late-stage therapeutic options limits the industry's capacity to meet clinical demand, thereby constraining revenue potential and hampering the sector's financial progress.

Market Trends

The integration of digital health platforms and connected smart inhalers is transforming patient management by moving from reactive treatment to proactive adherence monitoring. These technologies employ sensor-enabled devices to track medication use in real-time, sending data to healthcare providers to detect non-compliance and anticipate exacerbations before they happen. This digital ecosystem enables timely interventions and provides patients with actionable insights into their respiratory health, significantly enhancing clinical outcomes. According to ResMed's 'Q2 2024 Earnings Presentation' in January 2024, the company impacted over 170 million lives with its cloud-based software and digital health products in the preceding year, demonstrating the massive scale at which connected respiratory technologies are currently influencing patient care.

Simultaneously, the market is undergoing a vital transition toward sustainable low-carbon propellant devices, driven by regulatory pressures to reduce the environmental impact of hydrofluorocarbon-based inhalers. Manufacturers are actively reformulating their portfolios to replace high-global-warming-potential propellants with eco-friendly alternatives like HFA-152a, ensuring commercial viability amidst stricter environmental mandates. This strategic shift protects product lifecycles from potential legislative bans on carbon-intensive aerosols while meeting the growing demand for environmentally responsible healthcare solutions. As noted by Pharmaceutical Technology in April 2024, Chiesi Farmaceutici has invested €350 million to develop a new inhaler propellant expected to cut the company's Scope 3 emissions by 90% compared to 2019 levels.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc

Report Scope

In this report, the Global Lower Respiratory Tract Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lower Respiratory Tract Therapeutics Market, By Disease Type

• Asthma
• COPD
• Pneumonia
• Tuberculosis
• Bronchitis
• Others

Lower Respiratory Tract Therapeutics Market, By Drug Class

• Antibiotics
• Non-Steroidal Anti-Inflammatory Drugs
• Cough Suppressants
• Nasal Decongestants
• Others

Lower Respiratory Tract Therapeutics Market, By Route of Administration

• Oral
• Parenteral
• Others

Lower Respiratory Tract Therapeutics Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lower Respiratory Tract Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lower Respiratory Tract Therapeutics Market.

Available Customizations:

Global Lower Respiratory Tract Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lower Respiratory Tract Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
  • 5.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Lower Respiratory Tract Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Lower Respiratory Tract Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Lower Respiratory Tract Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Lower Respiratory Tract Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Lower Respiratory Tract Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Lower Respiratory Tract Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lower Respiratory Tract Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sanofi S.A
• 15.4. Pfizer Inc.
• 15.5. GSK plc
• 15.6. Novartis AG
• 15.7. AstraZeneca inc.
• 15.8. Johnson & Johnson
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Merck & Co., Inc

16. Strategic Recommendations

17. About Us & Disclaimer